Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial.
about
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesCapture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis.Future therapeutic targets in rheumatoid arthritis?Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-CThe interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.A Broad Blockade of Signaling from the IL-20 Family of Cytokines Potently Attenuates Collagen-Induced Arthritis.The IL-20 receptor axis in immune-mediated inflammatory arthritis: novel links between innate immune recognition and bone homeostasis.A review on interleukins: The key manipulators in rheumatoid arthritis.Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.IL-20 bone diseases involvement and therapeutic target potential.The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis
P2860
Q26775111-C44465DA-06CB-43F4-B9DA-A2095AA8134CQ28109583-47CDFFD7-1F8A-492A-BFB3-F6CE6A2A32E8Q33584720-9429D2A1-9713-4D64-A529-39C6F8714562Q33841419-F42D3377-31CC-4B1C-B2C1-5113C111F203Q36197435-67CEC120-716D-4BCB-9136-97CFED3F468DQ36679272-63C46186-FEB3-4FA3-9E01-1B1EE6B8FD45Q38697262-62C6A954-D010-4727-9BC4-7A041F7DCA9DQ38746702-5F72584C-CBB9-462A-A017-C6359235C68DQ38968418-EAD22628-33AD-47FC-A701-F2E37A49A9EBQ39029629-67DD6DBA-3A35-499A-96E8-F19909199582Q40162151-68E7B52A-2693-4EEA-8D6A-7EC0515A5144Q46275316-D2224CE6-FF41-48AC-AA41-058EC37CB0C7Q55052878-5FA96B3A-2581-442E-BC4A-70747A6FB271Q55121772-43451967-2E7E-441F-9095-6825F9E5C37FQ57492001-F191BDA3-11C9-488E-ADCF-CACA7FEC1049
P2860
Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and Safety of Anti-In ...... A Randomized Phase IIa Trial.
@en
type
label
Efficacy and Safety of Anti-In ...... A Randomized Phase IIa Trial.
@en
prefLabel
Efficacy and Safety of Anti-In ...... A Randomized Phase IIa Trial.
@en
P2093
P2860
P356
P1476
Efficacy and Safety of Anti-In ...... : A Randomized Phase IIa Trial
@en
P2093
Brian Bekker Hansen
Eva Dokoupilová
Marie Göthberg
Piotr Leszczynski
Xavier Valencia
P2860
P304
P356
10.1002/ART.39083
P577
2015-06-01T00:00:00Z